Back to Search
MICHAEL ROGAWSKI, M.D.
M.D.
Neurology Physician
NPI: 1538357033IndividualAccepts Medicare
Specialties, Licenses & Credentials
Neurology PhysicianPrimary
Psychiatry & Neurology — Neurology
Code: 2084N0400X
G88105(CA)
CMS Specialties
PrimaryNEUROLOGY
Education
YALE UNIVERSITY SCHOOL OF MEDICINE
Class of 1980
Research & Publications (20)
Convection-enhanced delivery in the treatment of epilepsy.
PMID 19332329·Neurotherapeutics·2009
6-review
Brivaracetam: a rational drug discovery success story.
PMID 18552880·Br J Pharmacol·2008
7-preclinical
New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels.
PMID 18590620·Curr Neurol Neurosci Rep·2008
6-review
Diverse mechanisms of antiepileptic drugs in the development pipeline.
PMID 16621450·Epilepsy Res·2006
6-review
The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.
PMID 15229516·Nat Med·2004
6-review
What is the rationale for new treatment strategies in Alzheimer's disease?
PMID 15241294·CNS Spectr·2004
4-observational
GluR5 kainate receptors, seizures, and the amygdala.
PMID 12724156·Ann N Y Acad Sci·2003
7-preclinical
The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
PMID 14530799·CNS Drug Rev·2003
6-review
Does P-glycoprotein play a role in pharmacoresistance to antiepileptic drugs?
PMID 12609240·Epilepsy Behav·2002
8-other
Neurosteroids and infantile spasms: the deoxycorticosterone hypothesis.
PMID 12040893·Int Rev Neurobiol·2002
6-review
Role of AMPA and GluR5 kainate receptors in the development and expression of amygdala kindling in the mouse.
PMID 11077068·Neuropharmacology·2001
7-preclinical
KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy.
PMID 10941184·Trends Neurosci·2000
6-review
Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents--toward an understanding of their favorable tolerability.
PMID 11026482·Amino Acids·2000
6-review
Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466.
PMID 19682025·Epilepsia·2010
7-preclinical
Neurosteroid replacement therapy for catamenial epilepsy.
PMID 19332335·Neurotherapeutics·2009
6-review
Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons.
PMID 19417176·J Pharmacol Exp Ther·2009
4-observational
Pathological alterations in GABAergic interneurons and reduced tonic inhibition in the basolateral amygdala during epileptogenesis.
PMID 19540312·Neuroscience·2009
7-preclinical
17beta-Nitro-5alpha-androstan-3alpha-ol and its 3beta-methyl derivative: neurosteroid analogs with potent anticonvulsant and anxiolytic activities.
PMID 19577558·Eur J Pharmacol·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4860 Y ST, SUITE 3700
SACRAMENTO, CA 95817 - Phone
- (916) 734-6275
Quick Facts
- NPI
- 1538357033
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 46
- Publications
- 20
Are you this provider?
Claim Your Profile